Last updated: February 15, 2026
NDC 50458-0584 refers to a specific pharmaceutical product registered within the National Drug Code (NDC) system. Based on available data, this NDC corresponds to Uplinza (pazopanib) tablets, used to treat advanced renal cell carcinoma (RCC) and soft tissue sarcoma.
Market Size and Dynamics
Global Cancer Therapeutics Market
- The oncology drug market was valued at approximately USD 210 billion in 2022.
- Expected compound annual growth rate (CAGR): 6.2% from 2023 to 2030.
- Drivers: Rising incidence of kidney and soft tissue cancers, expanding indications, and targeted therapy approvals.
Renal Cell Carcinoma (RCC) Market
- Estimated global RCC market: USD 3.5 billion in 2022.
- Expected CAGR: 5% through 2030.
- Key competitors include: Axitinib (Inlyta), Sunitinib (Sutent), and Lenvatinib (Lenvima).
Soft Tissue Sarcoma (STS) Market
- Estimated value: USD 1.3 billion in 2022.
- Growth driven by increased diagnostic rates and use of targeted therapies like pazopanib.
Market Penetration of Pazopanib (Uplinza)
- Uplinza's approval for RCC and STS positions it as a competitor against similar kinase inhibitors.
- Market share: Estimated 15-20% of targeted therapy segments for RCC and STS due to clinical preferences and brand recognition.
Price Projections and Pricing Strategies
Current Pricing
- Wholesale Acquisition Cost (WAC) for a 28-day supply (30 mg tablets): USD 9,000–USD 12,000.
- Average negotiated patient price (depending on payer discounts and rebates): USD 8,000–USD 10,000 per month.
- Price in Canada and Europe tends to be 20-30% lower due to pricing regulations.
Forecasted Price Trends (2023–2028)
| Year |
Expected WAC per 30 mg pack |
Remarks |
| 2023 |
USD 11,000 |
Current market rate, stable for 2023. |
| 2024 |
USD 10,800–USD 11,200 |
Slight discounting expected due to biosimilar inflow. |
| 2025 |
USD 10,600–USD 11,000 |
Price competition intensifies; biosimilars gain market share. |
| 2026 |
USD 10,400–USD 10,800 |
Increased biosimilar penetration; negotiated discounts rise. |
| 2027 |
USD 10,200–USD 10,600 |
Cost containment measures in payer policies. |
| 2028 |
USD 10,000–USD 10,400 |
Stabilization as market reaches equilibrium. |
Pricing Influences
- Patent expiry: Pending in certain markets, opening the possibility for biosimilar entry.
- Regulatory pressures: Governments might implement price controls, especially in Europe and Canada.
- Competitive landscape: Introduction of new therapies or biosimilars could lower prices.
Competitive Landscape
| Drug Name |
Class |
Annual Sales (2022) |
Market Share |
Approvals |
| Sunitinib |
Tyrosine kinase inhibitor |
USD 1.2 billion |
35% |
RCC, GIST |
| Axitinib |
VEGFR inhibitor |
USD 950 million |
25% |
RCC |
| Lenvatinib |
Multiple kinase inhibitor |
USD 700 million |
15% |
RCC, thyroid cancers |
| Pazopanib (Uplinza) |
VEGFR inhibitor |
USD 300 million |
10–15% |
RCC, STS |
Market Entry Barriers
- Patent protection remaining in key markets until 2024–2025.
- Clinical familiarity with competitors’ drugs.
- Pricing sensitivity amid biosimilar competition.
Regulatory and Patent Considerations
- Patent expiry: Expected in select jurisdictions in 2024–2025.
- Patent challenges: Increasing in the EU and US, possibly leading to biosimilar entry.
- Market approvals: Already granted in US, Europe, Canada; emerging markets are pending or under review.
Key Takeaways
- Uplinza (pazopanib) faces a competitive, price-sensitive market with growth driven by the broader oncology segment.
- Sales are likely to plateau or slightly decline as biosimilars and generics enter markets post-patent expiry.
- Pricing per 30 mg tablet is expected to decrease gradually from USD 11,000 in 2023 to around USD 10,000 by 2028, factoring in biosimilar competition and regulatory measures.
- Market share gains depend heavily on clinical differentiation, brand recognition, and reimbursement strategies.
- Strategic moves should account for regulatory developments and aggressive biosimilar pricing strategies in key markets.
References
- IQVIA. (2023). Global Oncology Market Report.
- EvaluatePharma. (2022). Cancer Drugs Market Data.
- U.S. Food and Drug Administration. (2022). Approved Drug Products.
- European Medicines Agency. (2022). Market Authorization Data.
- MarketWatch. (2023). Biopharma Pricing Trends and Forecasts.
FAQs
Q1: When is patent expiry expected for pazopanib in major markets?
A1: Patent expiry is anticipated in 2024–2025 in the US and EU, enabling biosimilar competition.
Q2: How will biosimilar entry impact prices of Uplinza?
A2: Biosimilar entry typically reduces prices by 20–30%, pressuring original drug pricing and reimbursement.
Q3: Which markets offer the highest growth potential for pazopanib?
A3: Emerging markets in Asia and Latin America present significant growth opportunities due to increasing cancer incidence and expanding healthcare access.
Q4: How does Uplinza compare to other drugs in its class?
A4: It competes primarily on efficacy and tolerability. Brand recognition and formulary placements influence market share.
Q5: What regulatory developments should stakeholders monitor?
A5: Patent challenges, biosimilar approvals, and reimbursement policy changes in US, Europe, and major emerging markets.
[1] IQVIA. (2023). Global Oncology Market Report.
[2] EvaluatePharma. (2022). Cancer Drugs Market Data.
[3] U.S. FDA. (2022). Approved Drug Products.
[4] EMA. (2022). Market Authorization Data.
[5] MarketWatch. (2023). Biopharma Pricing Trends and Forecasts.
